Loading clinical trials...

Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid | Clinical Trials | Clareo Health

COMPLETED

Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid

A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway

NCT01967160•Amgen

View on ClinicalTrials.gov

Summary

A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden, Denmark and Norway.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•≥ 18 years old
•diagnosed with cancer
•subsequent to cancer diagnosis, initiating cancer-related antiresorptive treatment during the treatment cohort identification period with XGEVA or zoledronic acid or switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates at the dose indicated for SRE prevention of less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)

Exclusion Criteria

•history of radiation treatment for head and neck cancer before a subject's potential index date
•hypercalcemia of malignancy as the sole indication for treatment with an anti-resorptive agent

Key Dates

Start Date

January 2, 2012

Primary Completion Date

August 5, 2019

Completion Date

August 5, 2019

Last Updated

June 22, 2023

Enrollment

2,560

ACTUAL participants

Conditions

Osteonecrosis of the JawInfection Leading to Hospitalization

Comparing Implant Retention Versus Removal for MRONJ at Implant Sites

NCT07435259

View study

NOT_YET_RECRUITINGNA

MRONJ and Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®)

NCT06984107

View study

COMPLETED

Medical and Surgical Treatment of MRONJ (Medication-related Osteonecrosis of the Jaw Bones)

NCT06917846

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 22, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid

Inclusion Criteria

Exclusion Criteria

Comparing Implant Retention Versus Removal for MRONJ at Implant Sites

MRONJ and Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®)

Medical and Surgical Treatment of MRONJ (Medication-related Osteonecrosis of the Jaw Bones)

Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw

Best Treatment Choice for Osteonecrosis of the Jaw

Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers